EUVIMEDEUVIMED entdecken
Open Access

Cancer Risk Associated With PTEN Pathogenic Variants Identified Using Multigene Hereditary Cancer Panel Testing

Shelly Cummings iD, Andrew Alfonso iD, Elisha Hughes iD, Matt Kucera, Brent Mabey, Nanda Singh, Charis Eng iD

JCO Precision Oncology · 2023

DOI: 10.1200/po.22.00415 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Precision Oncology, 2023. Verfasst von Shelly Cummings und 6 weiteren Autor:innen. Beteiligte Einrichtung: Myriad Genetics Inc, Salt Lake City, UT. Hauptthemen laut MEDLINE: Hamartoma Syndrome, Multiple, Breast Neoplasms, Thyroid Neoplasms. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE PTEN-associated clinical syndromes such as Cowden syndrome (CS) increase cancer risk and have historically been diagnosed based upon phenotypic criteria. Because not all patients clinically diagnosed with CS have PTEN pathogenic variants (PVs), and not all patients with PTEN PVs have been clinically diagnosed with CS, the cancer risk conferred by PTEN PVs calculated from cohorts of patients with clinical diagnoses of CS/CS-like phenotypes may be inaccurate. METHODS We assessed a consecutive cohort of 727,091 individuals tested clinically for hereditary cancer risk, with a multigene panel between September 2013 and February 2022. Multivariable logistic regression models accounting for personal and family cancer history, age, sex, and ancestry were used to quantify disease risks associated with PTEN PVs. RESULTS PTEN PVs were detected in 0.027% (193/727,091) of the study population, and were associated with a high risk of female breast cancer (odds ratio [OR], 7.88; 95% CI, 5.57 to 11.16; P = 2.3 × 10 −31 ), endometrial cancer (OR, 13.51; 95% CI, 8.77 to 20.83; P = 4.2 × 10 −32 ), thyroid cancer (OR, 4.88; 95% CI, 2.64 to 9.01; P = 4.0 × 10 −7 ), and colon polyposis (OR, 31.60; CI, 15.60 to 64.02; P = 9.0 × 10 −22 ). We observed modest evidence suggesting that PTEN PVs may be associated with ovarian cancer risk (OR, 3.77; 95% CI, 1.71 to 8.32; P = 9.9 × 10 −4 ). Among patients with similar personal/family history and ancestry, every 5-year increase in age of diagnosis decreased the likelihood of detecting a PTEN PV by roughly 60%. CONCLUSION We demonstrate that PTEN PVs are associated with significantly increased risk for a range of cancers. Together with the observation that PTEN PV carriers had earlier disease onset relative to otherwise comparable noncarriers, our results may guide screening protocols, inform risk-management strategies, and warrant enhanced surveillance approaches that improve clinical outcomes for PTEN PV carriers, regardless of their clinical presentation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hamartoma Syndrome, MultipleBreast NeoplasmsThyroid NeoplasmsHumansFemaleGenetic Predisposition to DiseasePhenotypePTEN Phosphohydrolase

Substanzen

PTEN protein, humanPTEN Phosphohydrolase

Autor:innen und Institutionen

  • Myriad Genetics Inc, Salt Lake City, UT.
  • Genomic Medicine Institute, Cleveland Clinic, Cleveland, OH.
  • Center for Personalized Genetic Healthcare, Cleveland Clinic Community Care, Cleveland, OH.
  • Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH.
  • Department of Genetics and Genome Sciences, and CASE Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH.

ORCID-Profile: Shelly Cummings, Andrew Alfonso, Elisha Hughes, Charis Eng

Zitieren

APA

Cummings, S., Alfonso, A., Hughes, E., Kucera, M., Mabey, B., Singh, N., & Eng, C. (2023). Cancer Risk Associated With PTEN Pathogenic Variants Identified Using Multigene Hereditary Cancer Panel Testing. JCO Precision Oncology. https://doi.org/10.1200/po.22.00415

Vancouver

Cummings S, Alfonso A, Hughes E, Kucera M, Mabey B, Singh N, et al. Cancer Risk Associated With PTEN Pathogenic Variants Identified Using Multigene Hereditary Cancer Panel Testing. JCO Precision Oncology. 2023. doi:10.1200/po.22.00415

BibTeX
@article{Cummings2023,
  author = {Cummings, Shelly and Alfonso, Andrew and Hughes, Elisha and Kucera, Matt and Mabey, Brent and Singh, Nanda and Eng, Charis},
  title = {Cancer Risk Associated With PTEN Pathogenic Variants Identified Using Multigene Hereditary Cancer Panel Testing},
  journal = {JCO Precision Oncology},
  year = {2023},
  doi = {10.1200/po.22.00415}
}
Kostenlos starten →